Background This quantitative meta-analysis was conducted to evaluate the efficacy and
safety of drug-eluting balloon (DEB) vs. uncoated balloon (UCB) in patients with …

Objective The optimal percutaneous treatment for femoropopliteal arterial occlusive disease
has yet to be assessed. This systematic review and meta-analysis assessed the efficacy of …

Objective An endovascular-first approach is usually recommended in femoropopliteal
occlusive disease. However, despite high technical success, plain old balloon angioplasty …

Background Drug‐coated balloon (DCB) angioplasty has emerged as a mainstay of therapy
for the treatment of peripheral arterial disease (PAD) involving the superficial femoral and …

Objectives: This study sought to assess the risk of target lesion revascularization (TLR) and
all-cause death at 12 months and at the maximum available follow-up. Secondary objectives …

Purpose The present meta-analysis evaluated the role of drug-coated balloon (DCB)
angioplasty for in-stent restenosis (ISR) in femoropopliteal artery disease. Materials and …

Background Randomized trials have shown comparable outcomes between second-
generation low-dose drug-coated balloons (LD-DCBs) and first-generation high-dose drug …

Background: The introduction of endovascular surgery has led to frequent stent use,
although in-stent restenosis (ISR) remains a challenging issue. Drug-coated balloon (DCB) …

Background Several multicenter industry-sponsored clinical trials reported satisfactory
results in the use of drug-coated balloons (DCBs) for treatment of femoropopliteal occlusive …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …